Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria (original) (raw)

Abstract

The prospective, multicentre Peripartum Cardiomyopathy in Nigeria (PEACE) registry originally demonstrated a high prevalence of peripartum cardiomyopathy (PPCM) among patients originating from Kano, North‐West Nigeria. In a post hoc analysis, we sought to determine if this phenomenon was characterized by a differential case profile and outcome among PPCM cases originating elsewhere.

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (28)

  1. Karaye KM, Habib AG, Sliwa K. Epidemi- ology of peripartum cardiomyopathy in Africa. Intern Cardiovas Forum J 2018; 15: 6-11.
  2. Desai D, Moodley J, Naidoo D. Peripartum cardiomyopathy: experi- ences at King Edward VIII Hospital, Durban, South Africa and a review of the literature. Trop Doct 1995; 25: 118-123.
  3. Mielniczuk LM, Williams K, Davis DR, Tang AS, Lemery R, Green MS, Gollob MH, Haddad H, Birnie DH. Frequency of peripartum cardiomyopathy. Am J Cardiol 2006; 97: 1765-1768.
  4. Kamiya CA, Kitakaze M, Ishibashi-Ueda H, Nakatani S, Murohara T, Tomoike H, Ikeda T. Different characteristics of peripartum cardiomyopathy between patients complicated with and without hypertensive disorders. Results from the Japanese Nationwide survey of peripar- tum cardiomyopathy. Circ J 2011; 75: 1975-1981.
  5. Karaye KM, Ishaq NA, Sa'idu H, Balarabe SA, Talle MA, Isa MS, Adamu UG, Umar H, Okolie HI, Shehu MN, Mohammed IY, Sanni B, Ogah OS, Oboirien I, Umuerri EM, Mankwe AC, Shidali VY, Njoku P, Dodiyi-Manuel S, Shogade TT, Olunuga T, Ojji D, Josephs V, Mbakwem AC, Tukur J, Isezuo SA. PEACE Registry In- vestigators. Incidence, clinical character- istics, and risk factors of peripartum cardiomyopathy in Nigeria: results from the peripartum cardiomyopathy in Nigeria registry. ESC Heart Fail 2020; 7: 235-243.
  6. National Population Commission. popu- lation.gov.ng. Archived from the original on October 10, 2017. Retrieved October 10, 2017
  7. McNamara DM, Elkayam U, Alharethi R, Damp J, Hsich E, Ewald G, Modi K, Alexis JD, Ramani GV, Semigran MJ, Haythe J, Markham DW, Marek J, Gorcsan J, Wu WC, Lin Y, Halder I, Pisarcik J, Cooper LT, Fett JD, IPAC In- vestigators. Clinical outcomes for peri- partum cardiomyopathy in North America: Results of the IPAC study (in- vestigations of pregnancy- associated cardiomyopathy). J Am Coll Cardiol 2015; 66: 905-914.
  8. Sliwa K, Petrie MC, van der Meer P, Mebzaa A, Hilfiker-Kleiner D, Jackson AM, Maggioni AP, Laroche C, Regitz- Zagrosek V, Schaufelberger M, Tavazzi L, Roos-Hesselink J, Seferovic P, van Spandonck-zwarts K, Mbakwem A, Boehm M, Mouquet PB, Johnson MR, Hamdan R, Ponikowski P, Van Veldhuisen DJ, Mcmurray JJ, Bauersachs J. Management and 6-month outcomes in women with peripartum cardiomyop- athy: an ESC EORP registry. Eur Heart J 2020; 41: 3787-3797.
  9. Karaye KM, Sa'idu H, Balarabe SA, Ishaq NA, Adamu UG, Mohammed IY, Oboirien I, Umuerri EM, Mankwe AC, Shidali VY, Njoku P, Dodiyi-Manuel S, Olunuga T, Josephs V, Mbakwem AC, Okolie H, Talle MA, Isa MS, Ogah OS, Stewart S. PEACE Registry Investigators. Clinical features and outcomes of peripartum cardiomy- opathy in Nigeria. J Am Coll Cardiol 2020; 76: 2352-2364.
  10. Karaye KM, Mohammed IY, Ogah OS, Basil N, Okeahialam BN. Rationale and design for the peripartum cardiomyopathy in Nigeria (PEACE) reg- istry. Intern Cardiovas Forum J 2017; 12: 12-17.
  11. World Medical Association Declaration of Helsinki. Ethical principles for medical research involving human subjects. J Postgrad Med 2002; 48: 206-208.
  12. Sliwa K, Hilfiker-Kleiner D, Petrie MC, Mebazaa A, Pieske B, Buchmann E, Regitz-Zagrosek V, Schaufelberger M, Tavazzi L, van Veldhuisen DJ, Watkins H, Shah AJ, Seferovic PM, Elkayam U, Pankuweit S, Papp Z, Mouquet F, McMurray JJ. Heart Failure Association of the European Society of Cardiology Working Group on Peripartum Cardio- myopathy. Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyop- athy: a position statement from the Heart Failure Association of the Euro- pean Society of Cardiology Working Group on peripartum cardiomyopathy. Eur J Heart Fail 2010; 12: 767-778.
  13. Bauersachs J, König T, van der Meer P, Petrie MC, Hilfiker-Kleiner D, Mbakwem A, Hamdan R, Jackson AM, Forsyth P, de Boer RA, Mueller C, Lyon AR, Lund LH, Piepoli MF, Heymans S, Chioncel O, Anker SD, Ponikowski P, Seferovic PM, Johnson MR, Mebazaa A, Sliwa K. Patho- physiology, diagnosis and management of peripartum cardiomyopathy: a posi- tion statement from the Heart Failure As- sociation of the European Society of Cardiology Study Group on peripartum cardiomyopathy. Eur J Heart Fail 2019; 21: 827-843.
  14. Karaye KM, Sa'idu H, Balarabe SA, Ishaq NA, Sanni B, Abubakar H, Mohammed BL, Abdulsalam T, Tukur J, Mohammed IY. Selenium supplementation in pa- tients with peripartum cardiomyopathy: a proof-of-concept trial. BMC Cardiovasc Disord 2020; 20: 457.
  15. Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardi- ography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 2015; 28: 1-39.
  16. Karaye KM, Lindmark K, Henein MY. One-year survival in Nigerians with peri- partum cardiomyopathy. Heart Views 2016; 17: 55-61.
  17. Blauwet LA, Libhaber E, Forster O, Tibazarwa K, Mebazaa A, Hilfiker- Kleiner D, Sliwa K. Predictors of out- come in 176 South African patients with peripartum cardiomyopathy. Heart 2013; 99: 308-313.
  18. Moulig V, Pfeffer TJ, Ricke-Hoch M, Schlothauer S, Koenig T, Schwab J, Ber- liner D, Pfister R, Michels G, Haghikia A, Falk CS, Duncker D, Veltmann C, Hilfiker-Kleiner D, Bauersachs J. Long- term follow-up in peripartum cardiomyopathy patients with contem- porary treatment: low mortality, high cardiac recovery, but significant cardio- vascular co-morbidities. Eur J Heart Fail 2019; 21: 1534-1542. [E-pub ahead of print].
  19. Fett JD, Christie LG, Carraway RD, Murphy JG. Five-year prospective study of the incidence and prognosis of peripartum cardiomyopathy at a single institution. Mayo Proc 2005; 80: 1602-1606.
  20. Schelbert EB, Elkayam U, Cooper LT, Givertz MM, Alexis JD, Briller J, Felker GM, Chaparro S, Kealey A, Pisarcik J, Fett JD, McNamara DM, Investigations of Pregnancy Associated Cardiomyopa- thy (IPAC) Investigators. Myocardial damage detected by late gadolinium en- hancement cardiac magnetic resonance is uncommon in peripartum cardiomyop- athy. J Am Heart Assoc 2017; 6: e005472.
  21. Karaye KM, Lindmark K, Henein MY. Right ventricular systolic dysfunction and remodelling in Nigerians with peri- partum cardiomyopathy: a longitudinal study. BMC Cardiovasc Disord 2016; 16: 27.
  22. Karaye KM, Yahaya IA, Lindmark K, Henein MY. Serum selenium and cerulo- plasmin in Nigerians with peripartum cardiomyopathy. Int J Mol Sci 2015; 16: 7644-7654.
  23. Sheppard R, Hsich E, Damp J, Elkayam U, Kealey A, Ramani G, Zucker M, Alexis JD, Horne BD, Hanley-Yanez K, Pisarcik J, Halder I, Fett JD, Mcnamara DM, IPAC Investigators. GNB3 C825T polymor- phism and myocardial recovery in peri- partum cardiomyopathy: results of the multicenter investigations of pregnancy- associated cardiomyopathy study. Circ Heart Fail 2016; 9: e002683.
  24. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, González-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the di- agnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891-975.
  25. Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med 1997; 336: 525-533.
  26. Rathore SS, Wang Y, Krumholz HM. Sex-based differences in the effect of di- goxin for the treatment of heart failure. N Engl J Med 2002; 347: 1403-1411.
  27. Adams KF Jr, Patterson JH, Gattis WA, O'Connor CM, Lee CR, Schwartz TA, Gheorghiade M. Relationship of serum digoxin concentration to mortality and morbidity in women in the digitalis in- vestigation group trial: a retrospective analysis. J Am Coll Cardiol 2005; 46: 497-504.
  28. Regional disparities in peripartum cardiomyopathy in NIgeria 11 ESC Heart Failure (2021) DOI: 10.1002/ehf2.13463